Results 1 to 10 of about 1,192 (104)

A Study Looking at How Missed Somatropin Injections Affect Growth in Children With Growth Hormone Deficiency: A Plain Language Summary of Publication [PDF]

Therapeutic Advances in Endocrinology and Metabolism
• Children with growth hormone deficiency (GHD) are often prescribed a growth hormone called somatropin to help them grow. • As prescribed, somatropin needs to be injected once a day under the skin.
Priti Jhingran
exaly   +3 more sources

Understanding the Burden of Weekly Somatrogon Injections Compared With Daily Somatropin Injections in Children With Growth Hormone Deficiency: A Plain Language Summary of Publication [PDF]

Therapeutic Advances in Endocrinology and Metabolism
• For children with growth hormone deficiency, once-weekly somatrogon injections were less of a burden than once-daily somatropin injections. • The safety of weekly somatrogon was similar to that of daily somatropin .
Aristides K. Maniatis, Mauri Carakushansky, Sonya Galcheva, Gnanagurudasan Prakasam, Larry A. Fox, Adriana Dankovcikova, Jane Loftus, Andrew A. Palladino, Maria de los Angeles Resa, Carrie Turich Taylor, Mehul T. Dattani, Jan Lebl   +11 more
exaly   +3 more sources

Comparing the Efficacy and Safety of Weekly Somatrogon With Daily Somatropin to Treat Children With Growth Hormone Deficiency: A Plain Language Summary of Publication [PDF]

Therapeutic Advances in Endocrinology and Metabolism
• The efficacy of weekly somatrogon injections was no different from that of daily somatropin injections to treat children who don’t make enough growth hormone to grow adequately. ○ Efficacy refers to how well a drug works in a clinical trial. ○ Children
Lawrence A Silverman, Aleksandra Pastrak
exaly   +3 more sources

Optimized Signal Peptide for Secretory Expression of Human Recombinant Somatropin in E. Coli [PDF]

Advanced Pharmaceutical Bulletin, 2023
Purpose: The human somatropin is a single-chain polypeptide with a pivotal role in various biological processes. Although Escherichia coli is considered as a preferred host for the production of human somatropin, the high expression of this protein in E.
Safar Farajnia, Davoud Farajzadeh, Zeinab Ahmady   +2 more
exaly   +2 more sources

Once-Weekly Somatrogon in Pediatric Growth Hormone Deficiency: Real-World Efficacy, Safety, and Quality-of-Life Findings [PDF]

JCRPE
Objective: To report real-world 6- and 12-month outcomes in children with growth hormone deficiency (GHD) treated with somatrogon or somatropin, including those who transitioned from somatropin to somatrogon.
Kübra Şen Küçük, Sebla Güneş, Mustafa Dinçer, Sercan Öztürk, Tolga Ünüvar, Ahmet Anık   +5 more
doaj   +2 more sources

Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study [PDF]

Endocrine Journal
Somatrogon is a long-acting recombinant human growth hormone approved in several countries, including Japan, for the treatment of children with growth hormone deficiency (GHD).
Reiko Horikawa, Toshiaki Tanaka, Yukihiro Hasegawa, Tohru Yorifuji, David Ng, Ron G. Rosenfeld, Yuko Hoshino, Akifumi Okayama, Nozomi Ebata, Masayoshi Hosoi, Shinichi Nakamuta, Roy Gomez, Aleksandra Pastrak, Orlando Castellanos   +13 more
doaj   +2 more sources

Persistence with daily growth hormone among children and adolescents with growth hormone deficiency in Japan. [PDF]

PLoS ONE
BackgroundPediatric growth hormone deficiency (pGHD) is treated with daily somatropin (recombinant human growth hormone) injections. High rates of discontinuation and poor adherence to treatment, which are associated with worse growth outcomes, have been
Jane Loftus, Jenifer Wogen, Darrin Benjumea, Priti Jhingran, Yong Chen, Jose Alvir, Michael P Wajnrajch, Kei Takasawa   +7 more
doaj   +2 more sources

Long‐Acting Growth Hormone Versus Daily Growth Hormone for Growth Hormone Deficiency Patients: A Network Meta‐Analysis of Clinical Trials [PDF]

Endocrinology, Diabetes & Metabolism
Introduction Current guidelines recognize daily recombinant human growth hormone (rhGH) as standard care and long‐acting growth hormone (LAGH) as an alternative for paediatric growth hormone deficiency (CHD).
Amir Abadi, Usra Ghanem, Hamid Ghanem, Ahmed Jalal Sawafta, Ayah Abulehia, Mohammed Ataya, Rahma Nairat, Alhammam Mohammad Sammour, Hazem Ayesh   +8 more
doaj   +2 more sources

Improvement in body composition of Japanese participants with Prader-Willi syndrome following somatropin treatment: an open-label, multi cohort Phase 3 study [PDF]

Endocrine Journal
Recombinant human growth hormone (GH; somatropin) treatment has beneficial effects on body composition in patients with Prader-Willi syndrome (PWS).
Masanobu Kawai, Nobuyuki Murakami, Reiko Horikawa, Koji Muroya, Yasuko Fujisawa, Yuko Hoshino, Akifumi Okayama, Takahiro Sato, Nozomi Ebata, Tsutomu Ogata   +9 more
doaj   +2 more sources

Comparing the efficacy and safety of weekly somatrogon with daily somatropin in Asian children living with growth hormone deficiency: a plain language summary of publication [PDF]

Therapeutic Advances in Endocrinology and Metabolism
Summary Key takeaways Children living with growth hormone deficiency (GHD) are usually treated with daily injections of a growth hormone called somatropin to help them grow normally. Somatrogon is a growth hormone treatment that only needs to be injected
Roy Gomez, Vaman Khadilkar, Jayashri Shembalkar, Der-Ming Chu, Cheol Woo Ko, Michael P. Wajnrajch, Ronnie Wang   +6 more
doaj   +2 more sources